

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP
VIRTUAL MEETING RECAP FOR FEBRUARY 4, 2026

There were 44 members and 2 guests at this virtual meeting. We also welcomed 2 new members.

Guest Speaker: Dr. Jens Hillengass MD, PhD. He is a Professor of Oncology and Internal Medicine, Vice Chair for Research, and Chief – Department of Medicine - Myeloma and Amyloidosis at Roswell Park Comprehensive Cancer Center, Buffalo NY, and Professor of Medicine, Division of Hematology and Oncology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo.

Topic: Imaging, bone disease, and physical exercise. Dr. Hillengass's slides are attached.

Upcoming Events:

International Myeloma Foundation

<https://www.myeloma.org/>

- **Supplemental Myeloma Support Groups**
 - **Multiple Myeloma Care Partner Support Group (virtual)**
 - **Feb 12 @ 7:00 pm ET**
 - **Las Voces de Mieloma**

- Feb 17 1:00 pm ET
- Living Solo and Strong with Myeloma
 - March 3 @ 6:00 pm ET
- Living Well with High Risk Multiple Myeloma
 - Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm ET. Next meeting Feb 19 @ 7:00 pm ET
- MGUS 4 US
 - Please email Emily Gordon at erg2172@cumc.columbia.edu if you have questions or for meeting information
- Smolder Bolder
 - March 9 2026 @ 7:30-9:30 pm ET
- Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)
 - Feb 10 @ 8:00-9:00 pm ET
- The Veterans with Myeloma Special Interest Group (Virtual)
 - Meets the 4th Wednesday of the month. For more information or to sign up for group emails please reach out to veterans@IMFsupport.org or visit our webpage at veterans.support.myeloma.org.
 - @ 5:00 pm ET

New Group!!!

Myeloma in the Middle

Starting February 2026

Myeloma in the Middle, launched in 2026, is a virtual support group for individuals living with multiple myeloma during an

active stage of life—while working, raising families, caring for others, and managing major responsibilities.

This group provides a confidential, peer-based space to talk about challenges that are often unique to this population, including work and career disruption, financial concerns, parenting, relationships, dating, and balancing treatment with daily life. The focus is on shared understanding, practical navigation, and connection—without pressure, comparison, or expectation.

Meets virtually on the third Tuesday of each month at 7:30PM Eastern. For more information or to sign up for group emails please reach out to MMintheMiddle@IMFsupport.org or visit our webpage at MMintheMiddle.support.myeloma.org.

- **Next Meeting**
- **Feb 17 @ 7:30 pm ET**

HeathTree Foundation for Multiple Myeloma

<https://healthtree.org/>

- Podcasts
 - **Myths vs. Facts about Diet in Multiple Myeloma**
 - **Dr. Urvi Shah**
 - **Feb 23, 2026 @ 10:00AM EST**

Triage Cancer

<https://trriagecancer.org/>

- Decisions About Work: Accommodations, Leave, Disability, & Retirement
 - **February 24, 2026 @ 1pm ET**
 - <https://trriagecancer.org/webinarreg-decisions-about-work>

Myeloma News:

FDA

- **Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval**
- <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/minimal-residual-disease-and-complete-response-multiple-myeloma-use-endpoints-support-accelerated>
- **FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma. Tri-specific Antibody...Anti GPRC5D/BCMA/CD3**
- **FDA Approves Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma**

- FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma. Bi-specific Antibody...Anti GPRDC5D/CD3
- FDA Clears IND Application for KLN-1010 in R/R Multiple Myeloma...Off the shelf CAR T-cell therapy

ASCO (American Society of Clinical Oncology)

- The Updated ASCO Living Guideline for Multiple Myeloma
 - The updated guideline covers:
 - Smoldering multiple myeloma (including high-risk)
 - Transplant-eligible multiple myeloma
 - Transplant-ineligible multiple myeloma
 - Relapsed/refractory multiple myeloma

New Jersey Monthly Magazine

- Article on Carvykti – Car t-cell Therapy
 - “NJ Biotech Firm May Have Found a Cure for Multiple Myeloma”
 - <https://njmonthly.com/articles/news/nj-biotech-firm-may-have-found-a-cure-for-multiple-myeloma/>

Support Group News:

- Next in person meeting at Steeplechase Cancer Center, Somerville NJ, is scheduled for April 15, 2026. The meeting time is 5:30-7:15pm EDT, in the first floor conference room. More information to follow as we get closer to April.
- Somerset Patriots Application for free tickets and box seating will be sent in in February.
- Upcoming meetings:
 - March 4 – Open Meeting (No speaker)
 - April 8 – Note meeting date! No meeting April 1, Passover
 - Speaker, Matt Mundy LMSW, Oncology Social Worker, NY Presbyterian Weill Cornell Medical Center
 - May 6 – MMRF (Multiple Myeloma Research Foundation)
 - Diagnostic Testing
 - June 3 – Ann Marie Robbins, Esquire
 - Estate Planning
 - July 1 – No meeting
 - August 5 – Open Meeting (No Speaker)
- The Palm Beach County Multiple Myeloma Support Group shared information on the Personal Air Purifier, “AirTamer.” Attached is information on AitTamer, should you be interested. As stated by their guest speaker, Phenelle Segal RN, CIC, FAPIC, Infection Control Expert, “the brand used by every myeloma patient I know across the country is AirTamer. You will see patients and family members wearing an AirTamer at every large myeloma conference you attend. I own one. I have never heard of a myeloma patient getting an airborne respiratory illness while wearing an AirTamer. This includes patients who no longer wear a mask on airplanes. They only wear AirTamer.”

- There is a 35% discount code shown in the attachment if you use the discount code MYEAIRTAMER. Air Tamer also donates to the IMF of 5% with each purchase.
- Book Suggestions
 - Fatal to Fearless by Kathy Guisti, Founder of the MMRF and 30 survivor of MM
 - Exercise in Uncertainty by Jonathan Gluck, Journalist and Editor, diagnosed with MM at age 38

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

VIRTUAL MEETING RECAP FOR FEBRUARY 4, 2026

INFORMATIONAL MYELOMA LINKS

FDA

- **Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval**
 - <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/minimal-residual-disease-and-complete-response-multiple-myeloma-use-endpoints-support-accelerated>

International Myeloma Foundation

<https://www.myeloma.org/>

- **The Updated ASCO Living Guideline for Multiple Myeloma**

- The updated guideline covers:
 - Smoldering multiple myeloma (including high-risk)
 - Transplant-eligible multiple myeloma
 - Transplant-ineligible multiple myeloma
 - Relapsed/refractory multiple myeloma
- December 2025 and January 2026: What's New in Myeloma?

Supplemental Myeloma Support Groups

- **Multiple Myeloma Care Partner Support Group (virtual)**
 - **Feb 12 @ 7:00 pm ET**
- **Las Voces de Mieloma**
 - **Feb 17 1:00 pm ET**
- **Living Solo and Strong with Myeloma**
 - **March 3 @ 6:00 pm ET**
- **Living Well with High Risk Multiple Myeloma**
 - **Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm ET. Next meeting Feb 19 @ 7:00 pm ET**
- **MGUS 4 US**
 - **Please email Emily Gordon at erg2172@cumc.columbia.edu if you have questions or for meeting information**
- **Smolder Bolder**
 - **March 9 2026 @ 7:30-9:30 pm ET**
- **Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)**
 - **Feb 10 @ 8:00-9:00 pm ET**
- **The Veterans with Myeloma Special Interest Group (Virtual)**

- **Meets the 4th Wednesday of the month. For more information or to sign up for group emails please reach out to veterans@IMFsupport.org or visit our webpage at veterans.support.myeloma.org.**
- **@ 5:00 pm ET**

New Group!!!

Myeloma in the Middle

Starting February 2026

Myeloma in the Middle, launched in 2026, is a virtual support group for individuals living with multiple myeloma during an active stage of life—while working, raising families, caring for others, and managing major responsibilities.

This group provides a confidential, peer-based space to talk about challenges that are often unique to this population, including work and career disruption, financial concerns, parenting, relationships, dating, and balancing treatment with daily life. The focus is on shared understanding, practical navigation, and connection—without pressure, comparison, or expectation.

We meet virtually on the third Tuesday of each month at 7:30PM Eastern. For more information or to sign up for group emails please reach out to MMintheMiddle@IMFsupport.org or visit our webpage at MMintheMiddle.support.myeloma.org.

- **Next Meeting**
- **Feb 17 @ 7:30 pm ET**

News

- **January 2026 – Myeloma News from the Journals**

- FDA Releases Draft Guidance for MRD and CR as Endpoints to Support Accelerated Approval for Myeloma Drugs
- FDA Approves Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- FDA Grants Fast Track Designation for Trispecific Antibody IBI3003 as Treatment for Relapsed/Refractory Multiple Myeloma
- The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of Directors

Events

Blogs

- From Abstracts to Hope: What ASH Means for Myeloma Patients
- December 2025 and January 2026: What's New in Myeloma?

Videos

- About the IMF
 - A Message to the Myeloma Community: IMF's President and CEO Shares Her Priorities and Hope for the Future
- ASCO/EHA
 - ASH
 - Top Myeloma Research Presented at ASH 2025: Easy-to-Understand Insights for Patients and Care Partners
 - KLN-1010 In Vivo CAR-T Therapy: Revolutionary Off-the-Shelf Treatment for Multiple Myeloma
 - MajesTEC-3: Teclistamab-Daratumumab Establishes New Standard of Care in Early Relapsed Myeloma

- Ask Dr. Durie
- Black Swan Research Initiative
- Community Conversations
- Community Workshops
- Emerging Therapies
 - Understanding ELREXFIO & Bispecific Antibodies for Multiple Myeloma
- Facebook Live
- Health Equity
- IMF History
- IMWG
- Inspirational
- Living Well With Myeloma
- M-Power
- Myeloma in a Minute
- Myeloma Made Simple
- Myeloma University
- NLB Webcasts
- Patient and Family Webinars
- Q&A
- Recent News and Developments
 - CAR T & Bispecific Antibodies: The Biggest Myeloma Advances from ASH 2025
- Treatments
- Trending Searches in Myeloma
 - What is MGUS? Understanding Monoclonal Gammopathy of Undetermined Significance in Multiple Myeloma
- What is Multiple Myeloma
 - Newly Diagnosed

- Tests and Staging
- Treatment
- Publications and Broadcasts
 - IMF Publications
 - IMF Broadcasts
 - Healthcare Professional Resource
- Resources and Support
 - IMF Support Network
 - Diversity, Equity, Inclusion
 - **External Resources**
 - **Drug Reimbursement Information and Assistance**
 - **Financial Assistance**
 - **Government Assistance**
 - **Guidance and Support**
 - **Housing and Travel Assistance**
 - **International Support**
 - **Legal Assistance**
 - **Pain Management**
 - **Transplant Resources**
 - **Other Cancer Resources**
- Veterans Against Myeloma
 - <https://www.myeloma.org/veterans-against-myeloma>
- M-Power
- **IMF's Infoline**
 - <https://www.myeloma.org/infoline>
- 800-452 CURE (2873)**
 - **Email: infoline@myeloma.org**
- IMF Medical Research
 - Black Swan Research Initiative
 - International Myeloma Working Group

- Asian Myeloma Network
- Road to the Cure
- Nurse Leadership Board
 - Nurse Leadership Board Members
 - Nurse Leadership Board Publications
 - Nursing Resources

Multiple Myeloma Research Foundation

<https://themmrf.org/>

- Mapping Out The Road Ahead...Kathy Guisti, MM patient and founder of MMRF and Anne Quinn Young, Chief Mission Officer, talk Myeloma
 - https://event.webcasts.com/viewer/event.jsp?ei=1748057&tp_key=2d250c1bce
- Blogs
 - ASH Annual Meeting 2025: How the MMRF is Driving New Discoveries and Collaborations
 - MMRF Launches Exciting New Program to Answer Critical Questions About Immune Therapies for Myeloma
 - Groundbreaking New MMRF-Led Studies Shed Light on Immune System's Role in Multiple Myeloma
 - Highlights From the 22nd IMS Annual Meeting
- Press Release
- Understanding Multiple Myeloma
- Navigating Diagnosis & Treatment
 - Clinical Studies and Emerging Therapies

- Finding Support
 - Patient Navigation Center
 - Myeloma Mentors
 - Education Resource Hub
 - Videos
 - New Myeloma Downloadable Fast Fact Cards
 - MMRF Patient Toolkit
 - Events
- Patient Navigation Center
- Myeloma Mentors
- Education Resource Hub
- Resources on Demand
- Videos
- Finding a Cure
- Patient Navigation Center
 - **Monday–Friday, 9 AM–7 PM ET 1-888-841-MMRF (6673)**
 - Information and Resources
 - Perspective on Treatments
 - Support
 - Get on the Right Path for You
 - Right Team
 - Right Tests
 - Right Treatment
 - Meet the Patient Navigators
 - Connect with a Myeloma Mentor

Myeloma Matters – MMRF Podcast

<https://www.youtube.com/playlist?list=PL6YqSpftWXYZht7lBSsLFkyvKsWAZSGq4>

- Great Topics! These are the newest...
 - CAR T-Cell Therapy at First Relapse
 - Newly Diagnosed with Multiple Myeloma? How to Navigate Your First Steps
 - Transition of Care Part 1: Going From Specialty Center to Community Team
 - Transition of Care Part 2: Logistics, Costs, and Self-Advocacy

HeathTree Foundation for Multiple Myeloma

<https://healthtree.org/>

- Education
 - News Articles
 - Conference Updates
- Educational Resources
 - University
 - Patient Guides
 - Expert Webinars
 - Many upcoming interesting webinars
 - Learn from Specialists
 - Find a Specialist
 - Podcasts
 - **Myths vs. Facts about Diet in Multiple Myeloma**

- **Dr. Urvi Shah**
- **Feb 23, 2026 @ 10:00AM EST**

- HealthTree Roundtables
- Additional Resources
 - Myeloma 101
 - Newly Diagnosed Guide
 - Financial Resources
 - Medications
 - Understanding Labs
- Community
 - Join the Conversation
 - Connect
 - Join a social platform specifically for Multiple Myeloma
 - Patient-to-Patient Connections
 - Coach
 - Find a personal coach to help navigate your Myeloma
 - Moves
 - Tackle challenges and crush your fitness goals together
 - Community Events
 - All Events
 - Join Educational Groups
 - Attend Topic Based Events to Further Your Cancer Education
 - Community Support Groups
 - Black and Hispanic Support
 - Black Myeloma Health
 - Resources in Spanish

- Cure Hub
 - Join Cure Hub
 - Track Your Disease
 - Connect Medical Records
 - See Tracked Labs
 - Record Side Effects
 - Find the Best Treatments
 - Treatment Options
 - Clinical Trial Finder
 - Twin Machine
 - Find Support
 - Find Side Effect Solutions
 - My Journal
 - Journal Your Multiple Myeloma Story
 - Register for Cure Tour

HealthTree University – YouTube

<https://www.youtube.com/c/HealthTreeUniversity>

- **ASH 2025 (98 Videos)**
 - <https://www.youtube.com/watch?v=mTI40Do1M80&list=PLJIQreXXYN7LDVENEKQ4Uv7ywCELKVJE>
- Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD
 - https://www.youtube.com/watch?v=rg_NXEQyx0M
- Rare Side Effect of CAR-T: Immune Effector Cell-Associated Enterocolitis (IEC-IC)
 - <https://www.youtube.com/watch?v=lvq6HFEBB3I>

- Finding Hidden Myeloma Using IMMunoPET Imaging Technology | Ola Landgren, MD, PhD
 - <https://www.youtube.com/watch?v=HP5ObhJ4nkw>
- Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD
 - <https://www.youtube.com/watch?v=ieT-Wo-ktAk>
- Living Longer With Myeloma: Real-World Clinic Results | James Berenson, MD
 - <https://www.youtube.com/watch?v=fm9EyGGzvUg>

SparkCures

<https://sparkcures.com/>

- Myeloma Support...Personalized.
- “Whether it's clinical trials, treatments or finding a myeloma specialist, we help you understand your myeloma options”
- 888-828-2206
- Now featuring trial options for MDS (Myelodysplastic Syndromes) and NTRK Gene Fusion Cancers

Myeloma Central

<https://www.myelomacentral.com/>

- [Standing in the Gaap](#)
 - Resources for African Americans
- Multiple Myeloma Resources for Nurses

Cure

<https://www.curetoday.com/tumor/myeloma>

- Latest News
 - Noninvasive Blood Test Launched for Myeloma MRD Monitoring- Quest Diagnostics
 - Tecvayli With Darzalex Could Be ‘Truly Transformative’ in Multiple Myeloma
 - FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma
 - FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma
 - FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma
 - Smoldering Multiple Myeloma: An Overview for Newly Diagnosed Patients
- Video Series
- Video Interviews
- Podcasts
- More News
 - Tecvayli Associated With Reduced Risk of Myeloma Progression or Death
- Myeloma Relapse: How Patients Cope Emotionally and Find New Hope
 - <https://www.curetoday.com/view/myeloma-relapse-how-patients-cope-emotionally-and-find-new-hope>

Cure – Cancer Horizons

<https://www.curetoday.com/cancer-horizons/myeloma>

- Choose “Myeloma”

- Understanding the Use of Bispecific Antibodies in Multiple Myeloma
- Communication is Key When Transitioning Multiple Myeloma Care
- What Is CAR-T Cell Therapy, and What Can Patients With Cancer Expect?

OncLive/OncLive Videos

<https://www.onclive.com/clinical/multiple-myeloma>

- Latest News
 - FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
 - SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
- Video Series
- Latest Videos
- Shorts
- Podcasts
 - Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP
 - Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD
- More News
 - Many great articles

Multiple Myeloma Hub

<https://multiplemyelomahub.com/>

- News
 - Symposium | Future directions with novel and established BCMA-DT in the multiple myeloma treatment paradigm
 - The role of MRD as an endpoint in clinical trials for MM
 - FDA grants fast track designation to investigational bispecific T-cell engager LBL-034 for RRMM
 - Symposium series | Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience
- Recent Content
- Most Read
- Multiple Myeloma Hub Symposiums
 - Symposium | Real-world insights and clinical experience with BCMA-directed therapies
 - <https://multiplemyelomahub.com/medical-information/symposium-real-world-insights-and-clinical-experience-with-bcmadirected-therapies>
 - Symposium | Practical considerations when sequencing novel agents and managing AEs with BCMA-directed therapies
 - <https://multiplemyelomahub.com/medical-information/symposium-practical-considerations-when-sequencing-novel-agents-and-managing-aes-with-bcma-directed-therapies>
- Steering Committee Meetings
- Drug Updates

- FDA fast track designation LBL-034

Multiple Myeloma Hub Podcast

<https://podcasts.apple.com/tz/podcast/multiple-myeloma-hub/id1513939744>

- What are the latest updates from the phase I trial of P-BCMA-ALLO1 for the treatment of RRMM?

Patient Power

<https://www.patientpower.info/multiple-myeloma>

American Society of Hematology (ASH)

<https://www.hematology.org/>

The ASCO Post

<https://ascopost.com/search-results/?q=myeloma>

- Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma
- **Multiple Myeloma: FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd**
- Evolving Treatment Landscape Spurs Living Guideline Update on Multiple Myeloma
- Dual Antigen Targeting of Drug-Resistant Extramedullary Myeloma
- **FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials**

- Multiple Myeloma: Sex Differences in Etiology and Clinical Presentation
- MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
- Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
- Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
- County-Level Obesity Prevalence May Predict Obesity-Related Cancer Rates in Young Adults
- Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers
- Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns

Blood

- Time to say adieu to FISH in myeloma diagnostics
 - <https://ashpublications.org/blood/article/147/3/221/565867/Time-to-say-adieu-to-FISH-in-myeloma-diagnostics>
- High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
 - <https://ashpublications.org/blood/article-abstract/147/3/266/547443/High-risk-genomic-consensus-validation-for?redirectedFrom=fulltext>
- High CTC, high-risk cytogenetics: a dangerous duo in MM?
 - <https://ashpublications.org/blood/article/147/4/325/565956/High-CTC-high-risk-cytogenetics-a-dangerous-duo-in>

- Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
 - <https://ashpublications.org/blood/article/147/4/431/547636/Circulating-tumor-cells-predict-myeloma-outcomes>
- A myeloma identity crisis yields daratumumab resistance
 - <https://ashpublications.org/blood/article/147/5/473/566208/A-myeloma-identity-crisis-yields-daratumumab>
- Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy
 - <https://ashpublications.org/blood/article-abstract/147/5/497/547403/Target-antigen-and-plasma-cell-phenotype-are?redirectedFrom=fulltext>
- The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma
 - <https://ashpublications.org/blood/article/147/5/474/566215/The-post-BCMA-playbook-RD118-GPRC5D-CAR-T-cells>
- The proteasome: a gatekeeper stabilizing BCMA expression
 - <https://ashpublications.org/blood/article/147/5/478/566209/The-proteasome-a-gatekeeper-stabilizing-BCMA>
- The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma
 - <https://ashpublications.org/blood/article/147/5/513/547852/The-fully-human-anti-GPRC5D-CAR-T-cell-therapy>
- Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens

- <https://ashpublications.org/blood/article/147/5/534/546138/Boosting-CAR-T-cell-efficacy-by-blocking>

Blood Cancer Talks - Podcast

<https://podcasts.apple.com/us/podcast/blood-cancer-talks/id1633724992>

The Patient Story

<https://thepatientstory.com/patient-stories/multiple-myeloma/>

Targeted Oncology

<https://www.targetedonc.com/clinical/multiple-myeloma-rc>

- Latest News
 - Nivolumab Shows Marginal ORR Following CAR T Failure in MM, NHL
 - FDA Issues Draft Guidance on MRD and CR End Points in Multiple Myeloma
 - FDA Grants Fast Track Designation to IBI3003 for R/R Multiple Myeloma
 - FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma
 - FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
- Video Series
- Latest Videos
 - Many ASH videos
- Shorts

- Podcasts
- More News
 - CoMMpass Data Set Illuminates Immune Cells' Role in Multiple Myeloma
 - Teclistamab Improves PFS, OS in First Relapse of Multiple Myeloma
 - Cell Atlas Identifies Immune Signatures Associated With Myeloma Outcomes
 - FDA Clears IND of Off-the-Shelf In Vivo CAR-T Therapy for R/R Myeloma
 - Sex-Based Differences in Multiple Myeloma: The Critical Role of Exosomal ncRNAs
 - The Future of Multiple Myeloma Research and Treatment Options
 - The Top Myeloma News of 2025

Cancernetwork

<https://www.cancernetwork.com/>

- “Cancer Focus – choose myeloma”
- Latest News
 - Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma
 - FDA Approves Subcutaneous Daratumumab Combination in NDMM
 - New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
 - How Would the Teclistamab Combo Approval Transform Multiple Myeloma?

- How is The Immune System a “Critical Player” in NDMM Outcomes?
- Video Series
- Video Interviews
- Shorts
- Podcasts
- More news
 - Data Show Potentially Higher Disease Burden Among Male NDMM Population
 - FDA Issues Guidance on MRD, CR Outcomes for Multiple Myeloma Approvals
 - Zevor-Cel Shows Long-Term Efficacy in Small R/R Multiple Myeloma Population
 - Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma
 - Teclistamab Extends Survival Vs SOC in Refractory Multiple Myeloma Trial
 - FDA Clears IND Application for KLN-1010 in R/R Multiple Myeloma
 - Subcutaneous Isatuximab Regimens Show Efficacy in R/R Multiple Myeloma

Patient Empowerment Network

<https://powerfulpatients.org/help-by-cancer-diagnosis/multiple-myeloma/>

Smart Patients

<https://www.smartpatients.com/>

HemOnc Pulse (Podcast)

<https://www.bloodcancerstoday.com/page/the-hemonc-pulse>

- Many great podcasts on Myeloma

Blood & Marrow Transplant Information Network

<https://bmtinfonet.org/>

- “Blood & Marrow Transplant Information Network (BMT InfoNet) is not-for-profit 501 (c) 3 organization dedicated to providing transplant and CAR T-cell therapy recipients and their loved ones with emotional support and high quality, easy-to-understand information about bone marrow, peripheral blood stem cell and cord blood transplant, and CAR T-cell therapy.”

Blood Cancer United (formerly LLS)

<https://bloodcancerunited.org/>

- The Bloodline with Blood Cancer United Podcast
<https://thebloodline.org/episodes/>
 - [Hope Meets Healing](#): Simple Practices for Stress Relief
- Blood Cancer United Vodcasts
<https://bloodcancerunited.org/resources/educational-resources/video/bloodline-breakthroughs-innovations-inspiration>
- Blood Cancer United Video and Webcasts

- <https://bloodcancerunited.org/resources/educational-resources/webcasts-videos>
 - Unite to Nourish: Nutrition Pre- and Post-Autologous Transplant

- **Weekly Online Chat:**
 - **Veterans Living with Blood Cancer**
 - **Every Tuesday Evening @ 8:00-10:00pm EDT**
 - **Online Chat for Caregivers:**
 - **Every Thursday Evening @ 8:00-10:00 pm EDT**
 - **Online Chat Living with Myeloma:**
 - **Every Monday Evening @ 8:00-10:00 pm EDT**
 - **Online Chat for Patients and Caregivers - Banding Together: Feeling Good Fridays**
 - **Every Friday @ 1:00-3:00 pm EDT**

Visit <https://bloodcancerunited.org/resources/patients/online-chats>

to register for the Chat you would like to attend***

- About Us
 - About Blood Cancer United
 - Featured Programs
 - Partners and Suppliers
 - Stories and News
- Financial Assistance
 - Financial Support
 - Additional Financial Assistance
 - Claims
- Local Groups
 - Find your Region

- Blood Cancers
 - Types of Blood Cancer
- Navigating Your Care
 - Adults
 - Young Adults
 - Children and Teens
- Resources
 - Patient Resources
 - Caregiver Resources
 - Healthcare and Professional Resources
 - Educational Resources
 - Support Resources
 - Blood Cancer Information Specialist
 - 1-800-955-4572
 - Clinical Trial Nurse Navigators
 - Registered Dietitian
 - Newsroom

Oncology Nursing News

<https://www.oncnursingnews.com/clinical/multiple-myeloma>

- Latest News
 - Sub-Q Daratumumab/VRd Wins Approval in Newly Diagnosed Multiple Myeloma
- Video Series
- Video Interviews
- Podcasts
- More News

VJHemonc (Video Journal of Oncology)

<https://www.vjhemonc.com/subject/multiple-myeloma/>

- The Multiple Myeloma Channel (Great information)
 - General Updates | The longest reported survival to date in any unselected group of patients with multiple myeloma
 - James Berenson
 - Latest Videos
 - Myeloma Sessions
 - Conferences
 - Topics
 - Podcasts
 - Features
 - VJ today

Triage Cancer

<https://tragecancer.org/>

- Events
 - **Decisions About Work: Accommodations, Leave, Disability, & Retirement**
 - **February 24, 2026 @ 1pm ET**
 - <https://tragecancer.org/webinarreg-decisions-about-work>
- Resources
- Materials
- Support

IMSOUND (International Myeloma Society Audio Short Series)

<https://www.myelomasociety.org/imsound/>

- “IMSound, the latest audio series from the International Myeloma Society! Each episode brings insights from top experts on crucial issues in the myeloma community”

Oncology Central

<https://www.oncology-central.com/?s=myeloma>

- Interesting Articles

Blood Cancers Today

<https://www.bloodcancerstoday.com/page/myeloma>

- LINKER-MM2 Trial Insights in Myeloma With Meletios-Athanasios Dimopoulos, MD
 - <https://www.bloodcancerstoday.com/post/linker-mm2-trial-insights-in-myeloma-with-meletios-athanasios-dimopoulos-md>
- Breaking Barriers in Relapsed Myeloma: Real-World Sequencing
 - <https://www.bloodcancerstoday.com/post/breaking-barriers-in-relapsed-myeloma-real-world-sequencing>
- Iberdomide Triplet Combination Shows Clinical Meaningful Activity in Myeloma

- <https://www.bloodcancerstoday.com/post/iberdomide-triplet-combination-shows-clinical-meaningful-activity-in-myeloma>
- AZD0120 Demonstrates Favorable Safety Profile in Phase1b Trial for People With Multiple Myeloma
 - <https://www.bloodcancerstoday.com/post/azd0120-demonstrates-favorable-safety-profile-in-phase1b-trial-for-people-with-multiple-myeloma>

X

- If you follow myeloma research, this matters: CARTITUDE-4 long-term data shows nearly 80% progression-free – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/201042147273340940>
4
- How can CAR T-cell therapy be made safer? – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/201146323120674847>
5
- People often ask, “Why isn’t CAR T given as a first treatment?”
 - <https://x.com/IMFmyeloma/status/201149624799191500>
0
- For those who’ve had many treatments, new research is bringing more hope—and safer options – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/201184250390161439>
9

- This is big. More than 85% of trial participants remained in remission 3 years later. Learn about a major bispecific antibody breakthrough – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/2012585899796648179>
- The bispecific antibody teclistamab plus daratumumab is being studied in the frontline setting – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/2012673568555893035>
- New options for people with hard-to-treat myeloma outside the bone (extramedullary) mean more hope and the potential for longer, better lives. Research is leading the way – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/2013643435215880310>
- The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma
 - <https://x.com/Abdallah81MD/status/2017629215516946791>
- "Both my husband and I were diagnosed with multiple myeloma. How is that possible?" – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/2018368235586887879>
- “Any alternatives to dexamethasone?” – Dr. Joseph Mikhael
 - <https://x.com/IMFmyeloma/status/2019184577533583644>
- “Can I still lift heavy at the gym?” – Dr. Joseph Mikhael

- <https://x.com/IMFmyeloma/status/201943074939332244>
[6](#)

The Fellow on Call Podcast

<https://www.thefellowoncall.com/>

- Management of Smoldering Myeloma
- Other great topics

Haematologica

- Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma
 - <https://haematologica.org/article/view/12172>

SOHO (Society of Hematologic Oncology)

- Sundar Jagannath, MD, defines 'cure' in multiple myeloma
 - https://www.youtube.com/watch?v=_1s8niTTboU

Healthcare Unfiltered (Emery University)

- CELMoDs in Multiple Myeloma
 - <https://www.youtube.com/watch?v=4k1AOPDJU8U>

National Library of Medicine

- Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma

- <https://pubmed.ncbi.nlm.nih.gov/41610311/>

Journal of Clinical Oncology

- Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis
 - <https://ascopubs.org/doi/10.1200/JCO-25-01713>

Cancer Nursing Today

- The Evolving Treatment Landscape: Nurse Practitioners Reflect on Progress in Hematologic Oncology at ASH 2025
 - <https://www.cancernursingtoday.com/post/the-evolving-treatment-landscape-nurse-practitioners-reflect-on-progress-in-hematologic-oncology-at-ash-2025>